Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -126.00M | -129.91M | -136.32M | -156.09M | -171.52M |
| Total Depreciation and Amortization | 11.99M | 12.49M | 12.90M | 14.65M | 16.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.28M | 18.66M | 21.07M | 37.58M | 43.96M |
| Change in Net Operating Assets | -3.21M | -4.33M | -3.74M | -6.71M | -4.08M |
| Cash from Operations | -101.94M | -103.10M | -106.08M | -110.57M | -115.61M |
| Capital Expenditure | -3.71M | -5.00M | -5.95M | -4.86M | -3.15M |
| Sale of Property, Plant, and Equipment | 240.00K | 362.00K | 362.00K | 125.00K | 122.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.52M | 96.71M | 116.76M | 111.09M | 113.57M |
| Cash from Investing | 87.05M | 92.08M | 111.17M | 106.35M | 110.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 412.00K | -- | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.49M | 5.49M | 5.49M | 6.93M | 4.46M |
| Cash from Financing | 5.90M | 5.49M | 5.49M | 6.93M | 4.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.00M | -5.53M | 10.57M | 2.71M | -618.00K |